KEAP1 and neoplasm: While studies indicate that there is ample evidence to support the involvement of NRF2 in cancer biology [37–40], the dominant focus in human research are somatic mutations in NRF2 and/or its repressor protein KEAP1, that confer either enhanced tumor escape from apoptosis or resistance to a variety of cancer chemotherapeutics [41].